This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== 3D woven fiber scaffold infiltrated with network hydrogels === One study discussed that the 3D woven fibers provide load bearing tribological properties of native cartilage where they are trying to achieve a near frictionless environment. Hydrogels are used as cell carriers because they can be readily seeded with cells. However, it is difficult to recreate both the biomechanical and chemical functions of natural tissue. Hydrogels of interpreting networks (IPN), are two different polymers mixed with one another on a molecular scale. This works to increase fracture toughness. They are ionically crosslinked networks with a special type of IPN that is capable of scattering mechanical energy while maintaining the shape of a hydrogel after deformation.
While not always successful alone, surgical excision when combined with other therapies dramatically decreases the recurrence rate. Examples of these therapies include but are not limited to radiation therapy, pressure therapy, and laser ablation. Pressure therapy following surgical excision has shown promising results, especially in keloids of the ear and earlobe. The mechanism of how exactly pressure therapy works is unknown at present, but many patients with keloid scars and lesions have benefited from it. Intralesional injection with a corticosteroid such as triamcinolone acetonide does appear to aid in the reduction of fibroblast activity, inflammation and pruritus. Tea tree oil, salt, or other topical oil does not affect keloid lesions. A 2022 systematic review included multiple studies on laser therapy for treating keloid scars. There was not enough evidence for the review authors to determine if laser therapy was more effective than other treatments. They were also unable to conclude whether laser therapy leads to more harm than benefits compared with no treatment or different kinds of treatment. Another 2022 systematic review compared silicone gel sheeting with no treatment, treatment with non-silicone gel sheeting, and treatment with intralesional injections of triamcinolone acetonide. The authors only found two small studies (36 participants in total) that compared these treatment options, so they were unable to determine which (if any) was more effective.
== Bromine-77 == Bromine-77 is the most stable radioisotope of bromine, with a half-life of 57.04 hours. Although β+ decay is possible for this isotope, about 99.3% of decays are by electron capture. Despite its complex emission spectrum, featuring strong gamma-ray emissions at 239, 297, 521, and 579 keV, 77Br was used in SPECT imaging in the 1970s. However, except for longer-term tracing, this is no longer considered practical due to the difficult collimator requirements and the proximity of the 521 keV line to the 511 keV annihilation radiation related to the β+ decay. The Auger electrons emitted during decay are nevertheless well-suited for radiotherapy, and 77Br can possibly be paired with the imaging-suited 76Br (produced as an impurity in common synthesis routes) for this application.
Sources: en.wikipedia.org
== Literature == Emanuel Gil-Av, Present status of enantiomeric analysis by gas chromatography, J. Mol. Evol. 6 (1975) 131–144. Nelu Grinberg: Emanuel Gil-Av (1916–1996): A man with a legacy, In: Chirality, 1998;10(5):372. Volker Schurig: In Memoriam – Emanuel Gil-Av. In: Journal of High Resolution Chromatography 19 (1996) 462. Volker Schurig: On the Centenary of Emanuel Gil-Av, Former Professor of the Weizmann Institute of Science and Pioneer of Enantioselective Chromatography, Isr. J. Chem. 56 (2016) 890–906.
CK1δ is involved in different developmental pathways, among them Wingless (Wnt)-, Hedgehog (Hh)-, and Hippo (Hpo)-pathways. In the Wnt pathway, CK1δ can phosphorylate different factors of the pathway, among them Dishevelled (Dvl), Axin, APC, and β-catenin. CK1δ also negatively influences the stability of β-catenin, after its phosphorylation on Ser-45, which permits GSK3β-mediated further phosphorylations and subsequent degradation.
The organisation was formed by the BSAC in 1889 as a paramilitary, mounted infantry force in order to provide protection for the Pioneer Column of settlers which moved into Mashonaland in 1890. In common with several colonial police forces such as the Royal Canadian Mounted Police (RCMP), it was modelled on the Royal Irish Constabulary (RIC), and its early officers were trained at the Police Depot in the Phoenix Park in Dublin. The unit played a central role in both the First Matabele War (1893) and the Second Matabele War (1896/97) with many troopers serving in the Jameson Raid. Until 1896 the force was called the British South Africa Company's Police. The BSAP operated originally in conjunction with the Southern Rhodesia Constabulary (SRC), the town police force for Salisbury (now Harare) and Bulawayo, but amalgamated with the SRC in 1909.
The first history of Christian Science appeared in McClure's magazine in 14 installments from January 1907 to June 1908, preceded by an editorial in December 1906. The essence of the articles, which included court documents and affidavits from Eddy's associates, was that Eddy's chief concern was money, and that she had derived Christian Science from Quimby. The material was also published as a book, The Life of Mary Baker G. Eddy and the History of Christian Science (1909). It became the key source for most non-church histories of the religion. The editor-in-chief assigned five writers to work on the series, including the novelist Willa Cather as the principal author. The book was kept out of print from early in its life by the Christian Science church, which bought the original manuscript. It was republished in 1971 by Baker Book House when its copyright expired, and again in 1993 by the University of Nebraska Press.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.